Contact Us Today!

617-573-3345

or Use Our Simple Online Form to Give Us Feedback

We welcome your comments and feedback. Please include contact information if you'd like a response.

Did you find this page helpful?





If you would like a response, please include your contact information.

CME Credit

COURSE EVALUATION  & CME CERTIFICATE INFORMATION

Evaluation must be completed for CME credit.  All electronic evaluations will be sent to the email address provided during registration process.

Or please use following address to access evaluation: https://www.research.net/s/3424509

Registrants will have three weeks to complete the online evaluation.  If you wish to gain CME credit after the 3 week grace period email the address below and reference the event/number (3424509).

CME certificates will be sent out three weeks after the completion of the course and online evaluation – where hours for credit are recorded.

Only one evaluation can be submitted per computer.  Problems with link please email: HMSCME_Evaluations@hms.harvard.edu

 

Course Description
The Harvard Department of Ophthalmology Annual Meeting and Alumni Reunion is a two-day course aimed at updating ophthalmologists, including ophthalmology residents and fellows, and vision researchers about the latest advances in clinical care and research in ophthalmology.  

The proposed activity is designed to address a wide range of gaps in knowledge of ophthalmic clinical practice and ophthalmic research. Our program is designed to proportionally cover the anterior and posterior segments of the eye as well as optics and visual function. The main goal is to familiarize the audience with new research and to update on emerging clinical practices in the field of ophthalmology. 

For anterior segment of the eye, the program will address the updates in novel methodologies in resident cataract surgery education, management of acute  Steven’s Johnson Syndrome, and  updates in basic research on corneal wound healing and regeneration, including the efforts that have been made in development of artificial cornea. 

For the posterior segment of the eye, the program will address new developments in the understanding of genetics of the retinal disorders and gene therapy approaches to treat retinitis pigmentosa. Gene therapy is a novel treatment currently in clinical trials for degenerations, and most ophthalmologists are not aware of the status of these trials and what can be offered to these patients who do not have any existing alternative treatment.  Uveal melanoma is a lethal disorder representing 3% of all melanoma cases.  Delays in diagnoses resulted in more aggressive treatment such as enucleation and potentially worse survival. The program will address the gaps in medical knowledge of diagnosing uveal melanoma and will discuss early detection signs and management aiming at closing this knowledge gap. 

Didactic lectures will be an efficient way to transmit the information regarding state of the art ophthalmology diagnosis and treatment and research developments.  The Q & A session following each lecture will allow for participants to clarify their understanding of the material presentation in real time which provides the best chance for them to feel familiar enough with the presentation so as to apply it in their practices.

Target Audience: Physicians, Researchers, Optometrists

Learning Objectives 
Upon completion of this activity, participants will be able to:

  • Evaluate current treatment approaches for (1) ocular involvement in Steven Johnson syndrome and tumor epidermal necrolysis and (2) iatrogenic diplopia into their care of patients. 
  • Integrate (1) new modes of imaging into care of patients with retinal disease and (2) diagnostic insights for ischemic optic neuropathy into care of patients with vision loss after surgery 
  • Utilize knowledge of proton beam therapy as a treatment for uveal melanoma in counseling patients with this disease.
  • Incorporate new developments in the genetics of retinitis pigmentosa, ocular immune privilege in the posterior segment of the eye, corneal regeneration and fibrosis, and retinal stem cell therapy into patient education so as to inform patients with relevant disorders about the ongoing research efforts in these areas.

The Harvard Medical School designates this live activity for a maximum of 11.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Harvard’s Disclosure Policy:
Harvard Medical School (HMS) adheres to all ACCME Essential Areas, Standards, and Policies. It is HMS’s policy that those who have influenced the content of a CME activity (e.g. planners, faculty, authors, reviewers and others) disclose all relevant financial relationships with commercial entities so that HMS may identify and resolve any conflicts of interest prior to the activity. These disclosures will be provided in the activity materials along with disclosure of any commercial support received for the activity. Additionally, faculty members have been instructed to disclose any limitations of data and unlabeled or investigational uses of products during their presentations.

ACGME Competencies:  This course is designed to enhance the following Accreditation Council of Graduate Medical Education competencies: Patient care and medical knowledge.

 

Page updated 7/7/14